A phase i clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer

Journal of Immunotherapy

Volumn 37, Issue 1, 2014, Pages 36-42

  Suzuki, Nobuaki ^a   Hazama, Shoichi ^a   Ueno, Tomio ^a   Matsui, Hiroto ^a   Shindo, Yoshitaro ^a   Iida, Michihisa ^a   Yoshimura, Kiyoshi ^a   Yoshino, Shigefumi ^a   Takeda, Kazuyoshi ^b   Oka, Masaaki ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Immunotherapy; KIF20A; Pancreatic cancer; Peptide; Phase I

Indexed keywords

GAMMA INTERFERON; GEMCITABINE; KINESIN LIKE PROTEIN KIF20A; PEPTIDE VACCINE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DRUG DOSE ESCALATION; DRUG SAFETY; FEMALE; HUMAN; LEUKOPENIA; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CANCER VACCINES; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; HUMANS; KINESIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PEPTIDE FRAGMENTS; T-LYMPHOCYTE SUBSETS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VACCINES, SUBUNIT;

EID: 84890937839     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000012     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58: 71-96. (Pubitemid 351521864)
2. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995 using the National Cancer Database. J Am Coll Surg. 1999;189: 1-7. (Pubitemid 29307735)
3. Bramhall SR, Allum WH, Jones AG, et al. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg. 1995;82: 111-115.
4. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol. 1996;7: 347-353. (Pubitemid 26246785)
5. Burris HA I, Moore MJ, Andersen J, et al. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol. 1997;15: 2403-2413. (Pubitemid 27251144)
6. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002; 20: 3270-3275. (Pubitemid 34831525)
7. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254: 1643-1647. (Pubitemid 21917508)
8. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J ExpMed. 1994;180: 347-352. (Pubitemid 24181083)
9. Shichijo S, Nakao M, Imai Y, et al. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med. 1998;187: 277-288. (Pubitemid 28080057)
10. Salgaller ML, Afshar A, Marincola FM, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res. 1995;55: 4972-4979.
11. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4: 321-327. (Pubitemid 28144091)
12. Suzuki N, Maeda Y, Tanaka S, et al. Detection of peptide-specific cytotoxic T-lymphocyte precursors used for specific immunotherapy of pancreatic cancer. Int J Cancer. 2002;98: 45-50. (Pubitemid 34113417)
13. Okabe H, Satoh S, Kato T, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res. 2001;61: 2129-2137. (Pubitemid 32692038)
14. Lin YM, Furukawa Y, Tsunoda T, et al. Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. Oncogene. 2002;21: 4120-4128. (Pubitemid 34712879)
15. Hasegawa S, Furukawa Y, Li M, et al. Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. Cancer Res. 2002;62: 7012-7017. (Pubitemid 35424095)
16. Taniuchi K, Nakagawa H, Nakamura T, et al. Downregulation of RAB6KIFL/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell. Cancer Res. 2005; 65: 105-112. (Pubitemid 40070801)
17. Okuno K, Sugiura F, Hida JI, et al. Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer. Exp Ther Med. 2011;2: 73-79.
18. Kono K, Iinuma H, Akutsu Y, et al. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med. 2012;10:141.
19. Janetzki S, Panageas KS, Ben-Porat L, et al. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother. 2008; 57: 303-315. (Pubitemid 350295382)
20. Matsuno S, Egawa S, Shibuya K, et al. Pancreatic cancer: current status of treatment and survival of 16071 patients diagnosed from 1981-1996, using Japanese National Pancreatic Cancer Database. Int J Clin Oncol. 2000;5: 153-157. (Pubitemid 30452406)
21. Pantalone D, Ragionieri I, Nesi G, et al. Improved survival in small pancreatic cancer. Dig Surg. 2001;18: 41-46. (Pubitemid 32217859)
22. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,20-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs. 1994;12: 29-34. (Pubitemid 24209062)
23. Carmichael J, Fink U, Russell RC, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 1996;73: 101-105. (Pubitemid 26026268)
24. Ueno H, Ioka T, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013; 31: 1640-1648.
25. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25: 1960-1966. (Pubitemid 46972777)
26. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364: 1817-1825.
27. Launay O, Surenaud M, Desaint C, et al. Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). Vaccine. 2013;31: 4406-4415.
28. Yamamoto K, Mine T, Katagiri K, et al. Immunological evaluation of personalized peptide vaccination for patients with pancreatic cancer. Oncol Rep. 2005;13: 875-883.
29. Miyazawa M, Ohsawa R, Tsunoda T, et al. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 2010; 101: 433-439.
30. Ishikawa H, Imano M, Shiraishi O, et al. Phase I clinical trial of vaccination with URLC10-derived peptide for patients with advanced esophageal cancer. Esophagus. 2012;9: 105-112.